Web Based Investigation of Natural History of Keloid Disorder, an Online Survey

Recruiting

• Conditions: Keloid

• Registration Number: NCT01423981
• Lead Sponsor: Tirgan, Michael H., M.D.

Brief Summary

This trial intends to gather very basic clinical information about keloid, its patterns of presentation, family history, ethnic background and correlation with the type of keloid, as well as prior treatment results that patients have had received.

Detailed Description

This will be a web based study, whereby patients will have to read and acknowledge the consent form online. Once patients agree and acknowledge the terms of the consent form, they will gain access to the questionnaire pages.

For those who are under age of 18, a parent or a legal guardian must sign the consent form and answer the online questions on behalf of the patient.

Study Timeline

• Study First Submitted: 2011-08-23
• Study First Submitted QC: 2011-08-24
• Study First Posted: 2011-08-26
• Study Start: 2011-11
• Status Verified: 2016-10
• Last Update Submitted: 2016-10-03
• Last Update Posted: 2016-10-04
• Primary Completion: 2030-12
• Study Completion: 2031-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 10000

Inclusion Criteria

1. Patients must have clinically confirmed diagnosis of keloid
2. Adults, age over 18
3. Parent or legal guardian may participate if patient is under the age of 18
4. Able and willing to complete a web based survey

Exclusion Criteria

• No one will be excluded from this study as long as the inclusion criteria are met.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determine the prevalence different phenotypes of keloid in participants.	Two years	Prevalence of different phenotypes of keloid will be measured in the study population and reported. Prevalence of familial keloid in the study population will also be determined and reported. Data will be analyzed to determine the distribution of keloid among different ethic groups. Data will be analyzed to report the percentage of patients who have had one or more treatments and the percentage of patients who have had successful treatments.

Trial Locations

Locations (1)

Michael H. Tirgan, MD; 🇺🇸 New York, New York, United States